Irish life sciences VC firm Seroba closes its Fund IV at €123M; will target up to 12 investments

Seroba, a Dublin-based life sciences venture capital firm, has closed its Seroba Fund IV at €123M. 

The fund aims to make up to 12 investments and has already invested in five companies, including Perfuze, Sibylla Biotech, Deciphex, Complement Therapeutics, and Artica Therapeutics, all focused on developing treatments for medical needs.

Seroba Fund IV will focus on early-stage investments in life sciences companies, primarily in Western Europe and selectively in North America. The fund’s main emphasis will be on biotech innovations, supporting ventures at their initial stages of development.

Investors supporting Seroba

In addition to current investors like the European Investment Fund (EIF), the Ireland Strategic Investment Fund (ISIF), Enterprise Ireland (EI), and Allied Irish Banks (AIB), Seroba Fund IV has also attracted new investors.

These include CDP Venture Capital, a U.S. corporate entity, and several family offices, further diversifying and strengthening the fund’s investor base.

Bruno Montanari, Partner at Seroba, says, “We are extremely pleased to complete a successful fundraising above our initial target, in what remains a challenging environment. We are grateful to our existing and new investors for their trust in our team and strategy, and we look forward to investing the fund to support entrepreneurs developing breakthrough medical solutions.”

Brief about Seroba

Seroba is a European life sciences venture capital firm that operates from Dublin, Paris, and Milan, focusing on biotech and medtech innovation. 

With its fourth Fund, Seroba aims to transform patient treatment, addressing unmet medical needs while creating value. 

The team, backed by industry expertise, collaborates with entrepreneurs and investors sharing the goal of improving human health and achieving financial success.

Since its inception, Seroba has invested in thirty-two life sciences companies, introducing twenty new medical devices and eight new therapeutics to the market. 

With a pan-European presence, the Seroba team evaluates a pipeline of investment opportunities within its designated focus areas.

Alan O’Connell, Partner at Seroba, says, “Life sciences remains a highly attractive sector for investors. It’s a great time to deploy the fund with rapid innovation driving high-quality investment opportunities.”

“We are indeed fortunate to work in an industry that helps to raise healthcare standards, allowing people to live better for longer while driving strong investment performance for our investors.”